Skip to main content

prt3789

·Code: PRT3789

prt3789: 2 clinical trials tracked.

prt3789 evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about prt3789, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 1 study sponsors
Clinical Trial Registry Records (2)

A Phase 2, Safety and Efficacy Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

NCT06682806Registry updated 2026-02-02·Phase 2·PRLD
Terminated

Primary endpoint: Safety and tolerability of PRT3789 in combination with pembrolizumab as measured by incidence of DLTs (Part 1)

Interventionalopen6 targetStarted 2025-06Completion 2026-019 sites · Spain, United StatesPrelude Therapeutics

A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3789 as Monotherapy and in Combination With Docetaxel in Participants With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

NCT05639751Registry updated 2025-10-16·Phase 1·PRLD
Completed

Primary endpoint: Dose limiting toxicity (DLT) of PRT3789 monotherapy and in combination with docetaxel

Interventionalopen135 enrolledStarted 2023-05Completion 2025-1032 sites · France, Netherlands, Singapore, Spain…Prelude Therapeutics